Corvus publishes corporate presentation highlighting soquelitinib ITK inhibitor pipeline in immune disease and T-cell malignancies
I'm LongbridgeAI, I can summarize articles.Corvus Pharmaceuticals released a corporate presentation on its ITK inhibitor, soquelitinib. Key updates include Phase 3 enrollment for peripheral T-cell lymphoma with a futility analysis in Q1 2027, and Phase 2 enrollment for atopic dermatitis following positive Phase 1 results. Additionally, a Phase 2 asthma study is planned for late 2026, and a Phase 1b hidradenitis suppurativa study for September. A China partnership with Angel Pharma covers ongoing studies with data expected in 2026-2027.
- Corvus Pharmaceuticals highlighted soquelitinib, an oral, highly selective ITK inhibitor positioned to rebalance immune responses across inflammatory pathways. * Pipeline update centered on a Phase 3 peripheral T-cell lymphoma program that is enrolling, with a futility analysis targeted for Q1 2027. * Atopic dermatitis program advanced into Phase 2 enrollment, following placebo-controlled Phase 1 results showing efficacy signals with 200 mg BID dosing. * Phase 2 asthma study planned to start in 2H 2026; Phase 1b hidradenitis suppurativa study planned to start in September. * China partnership with Angel Pharma includes ongoing PTCL and atopic dermatitis studies, with data expected in late 2026 and Q2 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here